• 1. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584
• 2. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002
• 3. An artificial photosynthesis system comprising a covalent triazine framework as an electron relay facilitator for photochemical carbon dioxide reduction?
  Siquan Zhang,Shengyao Wang,Liping Guo,Hao Chen,Bien Tan,Shangbin Jin J. Mater. Chem. C, 2020,8, 192-200
• 4. An ion-gating multinanochannel system based on a copper-responsive self-cleaving DNAzyme?
  Yang Chen,Di Zhou,Zheyi Meng,Jin Zhai Chem. Commun., 2016,52, 10020-10023
• 5. An anti-ultrasonic-stripping effect in confined micro/nanoscale cavities and its applications for efficient multiscale metallic patterning?
  Quan Xiang,Yiqin Chen,Zhiqin Li,Kaixi Bi,Guanhua Zhang,Huigao Duan Nanoscale, 2016,8, 19541-19550

Introduction to 4-Quinazolinecarboxylic acid, 2-phenyl- (CAS No. 7672-01-7) and Its Emerging Applications in Chemical Biology

4-Quinazolinecarboxylic acid, 2-phenyl-, identified by the chemical identifier CAS No. 7672-01-7, is a heterocyclic organic compound that has garnered significant attention in the field of chemical biology due to its unique structural properties and versatile biological activities. This compound belongs to the quinazoline family, a class of molecules known for their broad spectrum of pharmacological effects. The presence of a phenyl group at the 2-position and a carboxylic acid moiety at the 4-position endows this molecule with distinct chemical and biological characteristics, making it a valuable scaffold for drug discovery and medicinal chemistry research.

The quinazoline core is a fused bicyclic system consisting of a benzene ring and a pyrimidine ring, which is often modified to achieve specific biological functions. In the case of 4-Quinazolinecarboxylic acid, 2-phenyl-, the phenyl substitution enhances its interactions with biological targets, while the carboxylic acid group provides opportunities for further functionalization, such as esterification or amidation, to tailor its pharmacokinetic properties. These structural features have made this compound an attractive candidate for investigating novel therapeutic strategies.

Recent advancements in chemical biology have highlighted the potential of quinazoline derivatives as modulators of various biological pathways. Studies have demonstrated that compounds containing the quinazoline scaffold can exhibit inhibitory effects on enzymes and receptors involved in cancer progression, inflammation, and infectious diseases. Specifically, 4-Quinazolinecarboxylic acid, 2-phenyl- has been investigated for its ability to interact with kinases and other signaling proteins, which are critical in regulating cellular processes.

One of the most compelling areas of research involving 4-Quinazolinecarboxylic acid, 2-phenyl- is its application in oncology. Quinazoline derivatives have shown promise as kinase inhibitors, particularly in targeting tyrosine kinases that are overexpressed in cancer cells. The phenyl group in this compound enhances its binding affinity to these kinases by improving hydrophobic interactions with the active site. Additionally, the carboxylic acid group can participate in hydrogen bonding with key residues in the kinase domain, further stabilizing the enzyme-inhibitor complex.

Recent preclinical studies have reported that derivatives of 4-Quinazolinecarboxylic acid, 2-phenyl- can selectively inhibit the activity of abnormal tyrosine kinases without significantly affecting normal cellular processes. This selectivity is crucial for developing effective anticancer agents with minimal side effects. Furthermore, the structural flexibility of this compound allows for modifications that can enhance its solubility and bioavailability, which are essential factors for clinical translation.

Beyond oncology, 4-Quinazolinecarboxylic acid, 2-phenyl- has also been explored for its potential in treating inflammatory diseases and infectious disorders. The quinazoline scaffold has been shown to modulate inflammatory pathways by inhibiting enzymes such as cyclooxygenase (COX) and lipoxygenase (LOX), which are involved in producing pro-inflammatory mediators. Additionally, some derivatives have demonstrated antimicrobial properties by interfering with bacterial cell wall synthesis or DNA replication.

The synthesis of 4-Quinazolinecarboxylic acid, 2-phenyl- involves multi-step organic reactions that highlight the versatility of quinazoline chemistry. Common synthetic routes include condensation reactions between phenylamine derivatives and carbonyl compounds, followed by cyclization and subsequent functionalization to introduce the carboxylic acid group. These synthetic strategies allow for easy modification of the quinazoline core, enabling researchers to generate libraries of derivatives with tailored biological activities.

The growing interest in 4-Quinazolinecarboxylic acid, 2-phenyl- has spurred innovation in drug discovery methodologies. High-throughput screening (HTS) and computational modeling techniques have been employed to identify novel analogs with enhanced potency and selectivity. Additionally, structure-based drug design approaches leverage crystallographic data to understand how this compound interacts with biological targets at an atomic level. These efforts have led to the identification of several promising lead compounds that are being advanced into clinical development.

In conclusion,4-Quinazolinecarboxylic acid, CAS No. 7672-01, represents a fascinating example of how structural modifications can unlock new therapeutic possibilities. Its unique combination of a phenyl group and a carboxylic acid moiety makes it a versatile scaffold for drug discovery across multiple disease areas. As research continues to uncover new biological functions and synthetic strategies for quinazoline derivatives,4 Quinazolin ecarbox ylic aci d, 2 phen yl, is poised to play an increasingly important role in developing next-generation therapeutics.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)